Clinical Observation of Effects of Modified Xiangsha Liujunzi Tang Application on Adverse Reaction of Moderately/Highly Emetogenic Chemotherapy for Gastrointestinal Tumors

Fei SU; Yan-ni LOU; Li-ya LI; Zhi-qiang CHENG

doi:10.13422/j.cnki.syfjx.20212394

您当前的位置：

首页 >

文章列表页 >

Clinical Observation of Effects of Modified Xiangsha Liujunzi Tang Application on Adverse Reaction of Moderately/Highly Emetogenic Chemotherapy for Gastrointestinal Tumors

更新时间：2021-10-29

- Clinical Observation of Effects of Modified Xiangsha Liujunzi Tang Application on Adverse Reaction of Moderately/Highly Emetogenic Chemotherapy for Gastrointestinal Tumors
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 27, Issue 23, Pages: 104-110(2021)
- 作者机构：
  
  中日友好医院，北京 100029
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20212394
  CLC： R22;R242;R2-031;R246.5
- Received：13 August 2021，
  
  Published Online：19 October 2021，
  
  Published：05 December 2021
- 稿件说明：
移动端阅览
苏菲,娄彦妮,李利亚等.香砂六君子汤加减敷贴防治消化道肿瘤中、高致吐性化疗后副反应的临床观察[J].中国实验方剂学杂志,2021,27(23):104-110.

SU Fei,LOU Yan-ni,LI Li-ya,et al.Clinical Observation of Effects of Modified Xiangsha Liujunzi Tang Application on Adverse Reaction of Moderately/Highly Emetogenic Chemotherapy for Gastrointestinal Tumors[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(23):104-110.
苏菲,娄彦妮,李利亚等.香砂六君子汤加减敷贴防治消化道肿瘤中、高致吐性化疗后副反应的临床观察[J].中国实验方剂学杂志,2021,27(23):104-110. DOI： 10.13422/j.cnki.syfjx.20212394.

SU Fei,LOU Yan-ni,LI Li-ya,et al.Clinical Observation of Effects of Modified Xiangsha Liujunzi Tang Application on Adverse Reaction of Moderately/Highly Emetogenic Chemotherapy for Gastrointestinal Tumors[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(23):104-110. DOI： 10.13422/j.cnki.syfjx.20212394.

摘要

目的

探索香砂六君子汤加减贴剂防治消化道肿瘤患者中、高性致吐化疗方案后消化道反应、免疫机能及生存质量的改善情况。

方法

纳入2018年1月至2021年5月中日友好医院中西医结合肿瘤内科确诊消化道恶性肿瘤并行中、高性致吐化疗方案的住院患者140例，参照药物临床试验质量管理规范（GCP）按1∶1随机分为观察组（70例）和对照组（70例），入组者化疗前20 min均给予常规止吐处理1次（托烷司琼5 mg+地塞米松5 mg或甲泼尼龙40 mg），观察组患者在此基础上化疗后第2天加用香砂六君贴疗法1周（选穴为中脘、内关、足三里，每日6 h，每日更换敷贴），观察组患者同时贴敷安慰贴剂，观察化疗后两组患者治疗前及治疗后1周消化道反应分级情况、淋巴细胞亚群浓度及患者生存质量评分等数据，并进行统计分析。

结果

治疗后，与本组治疗前比较，两组患者化疗相关消化道反应分级均明显下降（

0.05）；与对照组治疗后相比较，观察组患者消化道反应分级下降更明显（

0.05）。观察组总有效率为81.43%（57/70），明显高于对照组的62.86%（44/70），差异有统计学意义（

=9.73，

0.05）。对观察组进行分层分析，与本组治疗前比较，不同种类肿瘤中食管癌和结直肠癌患者治疗后消化道反应分级明显下降（

0.05）；不同性别患者治疗后消化道反应分级明显均下降（

0.05）。免疫功能结果显示，与本组治疗前比较，对照组患者CD3

，CD4

，CD8

，NK细胞亚群浓度差异均无统计学意义，观察组患者CD3

，CD4

，NK细胞亚群明显升高，且优于对照组（

0.05）。与对照组比较，香砂六君贴观察组的生存质量Karnofsky评分明显升高，生存质量改善（

0.05）。

结论

香砂六君贴可降低消化道肿瘤患者中、高性致吐化疗方案后消化道反应分级、改善患者免疫机能及提高生存质量；中医外治穴位贴敷疗法值得临床推广应用。

Abstract

Objective

To investigate the effects of external application of modified Xiangsha Liujunzi Tang in improving gastrointestinal reaction，immune function， and quality of life in patients with gastrointestinal tumors after moderately/highly emetogenic chemotherapy.

Method

A total of 140 inpatients （from January 2018 to May 2021） with gastrointestinal malignancies diagnosed by the Oncology Department of Integrated Traditional Chinese and Western Medicine of China-Japan Friendship Hospital and treated with moderately/highly emetogenic chemotherapy were randomly divided into an experimental group （

=70） and a control group （

=70） according to the Good Clinical Practice （GCP）. Participants were given routine antiemetic treatment once 20 minutes before chemotherapy （tropisetron 5 mg + dexamethasone 5 mg or methylprednisolone 40 mg）. On this basis， the patients in the experimental group were treated with external application of modified Xiangsha Liujunzi Tang for 1 week on the second day after chemotherapy （the selected points were Zhongwan， Neiguan and Zusanli， 6 hours a day， and the application was changed every day）， and the patients in the control group were applied with comfort patch at the same time. The gastrointestinal reaction grade， subset concentration of lymphocytes， and Karnofsky score in two groups before and one week after chemotherapy were recorded， and all data were analyzed by SPSS 19.0 statistical software.

Result

The grades of chemotherapy-related gastrointestinal reaction in two groups after treatment decreased as compared with that before treatment （

0.05）. The experimental group was superior to the control group after treatment in terms of grade decrease （

0.05）. The total response rate of the experimental group was 81.43% （57/70）， higher than 62.86% （44/70） in the control group （

=9.73，

0.05）. Stratified analysis was performed on the experimental group. Compared with the conditions before treatment， the grade of gastrointestinal reaction in patients with esophageal cancer and colorectal cancer of the experimental group decreased after treatment （

0.05）， and that in patients of different genders decreased after treatment （

0.05）. The results of immune function showed that there was no significant difference in the concentrations of CD3

， CD4

， CD8

， and NK cell subsets of the control group before and after treatment， while the concentrations of CD3

， CD4

， and NK cell subsets of the experimental group were higher than those before treatment and even superior to those in the control group （

0.05）. The Karnofsky score of quality of life in the experimental group was higher than that in the control group， with quality of life improved （

0.05）.

Conclusion

External application of modified Xiangsha Liujunzi can improve the gastrointestinal reaction，immune function， and quality of life of patients with gastrointestinal tumors after moderately/highly emetogenic chemotherapy.

关键词

Keywords

references

ARNOLD M ， ABNET C C ， NEALE R E ， et al . Global burden of 5 major types of gastrointestinal cancer ［J］. Gastroenterology ， 2020 ， 159 （ 1 ）： 335 - 349 .

SUNG H ， FERLAY J ， SIEGEL R L ， et al . Global cancer statistics 2020：global cancer estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

LORUSSO V ， RUSSO A ， GIOTTA F ， et al . Management of chemotherapy-induced nausea and vomiting （CINV）：a short review on the role of Netupitant-Palonosetron（NEPA）［J］. Core Evid ， 2020 ， 15 ： 21 - 29 .

NAITO Y ， KAI Y ， ISHIKAWA T ， et al . Chemotherapy-induced nausea and vomiting in patients with breast cancer：a prospective cohort study ［J］. Breast Cancer ， 2020 ， 27 （ 1 ）： 122 - 128 .

吴文娟，李桂香 . 恶性肿瘤化疗相关性恶心呕吐的防治研究［J］. 兰州大学学报：医学版， 2021 ， 47 （ 3 ）： 46 - 50 .

RAZVI Y ， CHAN S ， MCFARLANE T ， et al . ASCO，NCCN，MASCC/ESMO：a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients ［J］. Support Care Cancer ， 2019 ， 27 （ 1 ）： 87 - 95 .

季进锋，许春明，施永杰，等 . 姜夏止逆方经鼻嗅疗法联合帕洛诺司琼防治化疗所致恶心呕吐的临床研究［J］. 中医药导报， 2021 ， 27 （ 5 ）： 95 - 99 .

胡中韦，黄伟，司海龙，等 . 化疗相关性呕吐的中西医治疗进展［J］. 辽宁中医杂志， 2020 ， 47 （ 10 ）： 217 - 221 .

国文文，周天，张可睿，等 . 灸法治疗化疗相关性恶心呕吐临床研究概况［J］. 辽宁中医药大学学报， 2021 ， 23 （ 3 ）： 123 - 126 .

BASCH E ， REEVE B B ， MITCHELL S A ， et al . Development of the National Cancer Institute's patient- reported outcomes version of the commonterminology for adverse events （PRO-CTCAE）［J］. J Natl Cancer Inst ， 2014 ， 106 （ 9 ）： 1 - 11 .

郑筱萸 . 中药新药临床研究指导原则［M］. 北京：中国医药科技出版社， 2002 ： 332 - 341 ．

WANG X D ， ZHANG P T . Discussion on the hierarchical diagnostic model of TCM syndromes ［J］. Chin J Trad Chin Med Pharm ， 2017 （ 32 ）： 1209 - 1213 ．

HESKETH P J ， KRIS M G ， BASCH E ， et al . Antiemetics：American society of clinical oncology clinical practice guideline update ［J］. J Clin Oncol ， 2017 ， 35 （ 28 ）： 3240 - 3261 .

BEAVER C C ， MAGNAN M A . Managing chemotherapy side effects：achieving reliable and equitable outcomes ［J］. Clin J Oncol Nurs ， 2016 ， 20 （ 6 ）： 589 - 591 .

周松晶，史佳，韩平 . 中药穴位贴敷联合托烷司琼治疗肿瘤化疗致临床症状的随机对照研究［J］. 湖北中医药大学学报， 2021 ， 23 （ 2 ）： 82 - 85 .

王拓然，韩颖，刘兵，等 . 穴位凝胶贴膏贴敷疗法治疗失眠临床观察［J］. 中国针灸， 2021 ， 41 （ 5 ）： 505 - 509 .

苏菲，程志强，李利亚，等 . 温经穴位贴联合止吐药防治化疗后消化道反应的单中心随机对照研究［J］. 中国新药杂志， 2020 ， 29 （ 4 ）： 408 - 412 .

张雅丽 . 内关、中脘、足三里穴揿针针刺减轻消化内科患者恶心呕吐症状效果观察［J］. 临床医药文献电子杂志， 2020 ， 7 （ 45 ）： 60 - 61 .

张雪丽 . 耳穴贴压对化疗相关性恶心呕吐的缓解作用及对抑郁、焦虑的影响［J］. 中国中医药科技， 2020 ， 27 （ 3 ）： 468 - 470 .

廖天华，胡联民，余昭胜，等 . 穴位贴敷联合注射用格拉司琼防治化疗相关性恶心呕吐30例临床观察［J］. 中医药导报， 2013 ， 19 （ 2 ）： 76 - 77 .

师林，黄圆圆，柯斌 . 加味龟鹿二仙胶汤联合顺铂对Lewis肺癌小鼠免疫功能的影响［J］. 中药材， 2021 （ 2 ）： 454 - 457 .

YASUMARU C C ， XAVIER J G ， STREFEZZI R F ， et al . Intratumoral T-lymphocyte subsets in canine oral melanoma and their association with clinical and histopathological parameters ［J］. Vet Pathol ， 2021 ， 58 （ 3 ）： 491 - 502 .

HOLTHOF L C ， STIKVOORT A ， VAN DER HORST H J ， et al . Bone marrow mesenchymal stromal cell-mediated resistance in multiple myeloma against NK cells can be overcome by introduction of CD38-CAR or TRAIL-variant ［J］. Hema Sphere ， 2021 ， 5 （ 5 ）： e561 .

马继红，蒋林剑，刘翼，等 . 穴位敷贴疗法对中晚期肿瘤合并失眠患者生活质量及睡眠质量的影响［J］. 广西中医药， 2021 ， 44 （ 2 ）： 12 - 14 .

王玲玲，王英浩，左政，等 . 中医治疗乳腺癌术后化疗引起恶心呕吐的概述［J］. 世界中医药， 2019 ， 14 （ 8 ）： 1963 - 1968 .

冯慧敏，李成义，何军刚，等 . 红芪化学成分和药理作用研究进展及质量标志物（Q-Marker）的预测分析［J］. 中草药， 2021 ， 52 （ 9 ）： 2831 - 2842 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Xiangsha Liujunzi Tang in Regulation of RhoA/ROCK2/MYPT1 Pathway to Improve Gastric Motility in Rats with Functional Dyspepsia

Treatment of Diabetic Depression with Traditional Chinese Medicine：A Review

Effect and Mechanism of Xiangsha Liujunzi Tang on Lipid Deposition in Liver of ApoE^-/-AS Mice by Affecting Long Noncoding RNA-HC/miR-130b and to Regulate Cholesterol Metabolism

Effect of Erxian Shengbai Decoction Combined with Huangqi Huanagshan Soup on Leukopenia After Chemotherapy and Regulatory Effect on Immunity

Effect of Modified Qingzao Jiufei Tang on Quality of Life and Survival Period of Patients with Non-small Cell Lung Cancer

Related Author

LIU Mengya

CHENG Yingxia

BAI Min

ZHAO Linna

LI Runfa

AN Yaorong

DUAN Yongqiang

LI Yarong

Related Institution

College of Traditional Chinese Medicine，Ningxia Medical University

Gansu Province Laboratory Animal Industry Technology Center

Gansu University of Chinese Medicine

Shandong University of Traditional Chinese Medicine（TCM）

Shandong TCM Classic Prescription Collaborative Innovation Center， Shandong University of TCM

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰